VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

ALK peptide vaccine

Vaccine Information

Vaccine Name: ALK peptide vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Type: Subunit vaccine
Status: Research
Host Species for Licensed Use: None
Antigen: ALK antigens (Mota et al., 2023)
Immunization Route: Other
Description: A single-peptide vaccination restored priming of Anaplastic lymphoma kinase (ALK)-specific CD8+ T cells, eradicated lung tumors in combination with ALK tyrosine kinase inhibitors (TKIs) and prevented metastatic dissemination of tumors to the brain. Human ALK peptides are displayed by HLA-A*02:01 and HLA-B*07:02 molecules. The peptides are immunogenic and recognized by CD8+ T cells from individuals with non-small cell lung cancer (NSCLC). (Mota et al., 2023)

Host Response

References

Mota et al., 2023: Mota I, Patrucco E, Mastini C, Mahadevan NR, Thai TC, Bergaggio E, Cheong TC, Leonardi G, Karaca-Atabay E, Campisi M, Poggio T, Menotti M, Ambrogio C, Longo DL, Klaeger S, Keshishian H, Sztupinszki ZM, Szallasi Z, Keskin DB, Duke-Cohan JS, Reinhold B, Carr SA, Wu CJ, Moynihan KD, Irvine DJ, Barbie DA, Reinherz EL, Voena C, Awad MM, Blasco RB, Chiarle R. ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nature cancer. 2023; 4(7); 1016-1035. [PubMed: 37430060].